Intravenous immunoglobulin G (IVIG) inhibits IL-1- and TNF-α-dependent, but not chemotactic-factor-stimulated, neutrophil transendothelial migration

Clinical Immunology

Volumn 141, Issue 2, 2011, Pages 187-196

  Issekutz, Andrew C ^a   Rowter, Derek ^a   MacMillan, Heather F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anti inflammatory; Endothelium; IGIV; Inflammation; Leukocyte; Recruitment

Indexed keywords

CD11B ANTIGEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; L SELECTIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INCUBATION TIME; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TREATMENT OUTCOME; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION;

ANTIGENS, CD11B; CELL ADHESION; CELLS, CULTURED; CHEMOTACTIC FACTORS; COMPLEMENT C5A; ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; INFECTION; INFLAMMATION; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-8; L-SELECTIN; NEUTROPHILS; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 80054845468     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.08.003     Document Type: Article

References (39)

1. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schoni M., Vest M., Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981, 1:1228-1231.
2. Darabi K., Abdel-Wahab O., Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006, 46:741-753.
3. Negi V.S., Elluru S., Siberil S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., Lacroix-Desmazes S., Bayry J., Kaveri S.V. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J. Clin. Immunol. 2007, 27:233-245.
4. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., Nelson R.P., Patel D.D., Secord E., Sorensen R.U., Wasserman R.L., Cunningham-Rundles C. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol. 2006, 117:S525-S553.
5. Bayry J., Kazatchkine M.D., Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat. Clin. Pract. Neurol. 2007, 3:120-121.
6. Barnes P.J. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol. 2007, 119:1055-1062. quiz 1063-1064.
7. O'Donnell R., Breen D., Wilson S., Djukanovic R. Inflammatory cells in the airways in COPD. Thorax 2006, 61:448-454.
8. Poubelle P.E., Chakravarti A., Fernandes M.J., Doiron K., Marceau A.A. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils. Arthritis Res. Ther. 2007, 9:R25.
9. Frenette P.S., Wagner D.D. Adhesion molecules--Part 1. N. Engl. J. Med. 1996, 334:1526-1529.
10. Frenette P.S., Wagner D.D. Adhesion molecules-Part II: blood vessels and blood cells. N. Engl. J. Med. 1996, 335:43-45.
11. Luster A.D. Chemokines--chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 1998, 338:436-445.
12. Luster A.D., Alon R., von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat. Immunol. 2005, 6:1182-1190.
13. Smith C.W. 3. Adhesion molecules and receptors. J. Allergy Clin. Immunol. 2008, 121:S375-S379. quiz S414.
14. Wadhwa M., Meager A., Dilger P., Bird C., Dolman C., Das R.G., Thorpe R. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1α and interferon-α but not other cytokines in human immunoglobulin preparations. Immunology 2000, 99:113-123.
15. Vassilev T.L., Kazatchkine M.D., Van Huyen J.P., Mekrache M., Bonnin E., Mani J.C., Lecroubier C., Korinth D., Baruch D., Schriever F., Kaveri S.V. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp. Blood 1999, 93:3624-3631.
16. Macmillan H.F., Rowter D., Lee T., Issekutz A.C. Intravenous immunoglobulin G selectively inhibits IL-1α-induced neutrophil-endothelial cell adhesion. Autoimmunity 2010, 43:619-627.
17. Issekutz A.C., Rowter D., Springer T.A. Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J. Leukoc. Biol. 1999, 65:117-126.
18. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 1973, 52:2745-2756.
19. Smith C.W. Leukocyte-endothelial cell interactions. Semin. Hematol. 1993, 30:45-53. discussion 54-55.
20. Dinarello C.A. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr. Opin. Pharmacol. 2004, 4:378-385.
21. Apostolaki M., Armaka M., Victoratos P., Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 2010, 11:1-26.
22. Morzycki W., Sadowska J., Issekutz A.C. Interleukin-1 and tumour necrosis factor α induced polymorphonuclear leukocyte-endothelial cell adhesion and transendothelial migration in vitro: the effect of apical versus basal monolayer stimulation. Immunol. Lett. 1990, 25:331-340.
23. 1 in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment. Transfusion 2010, 50:547-555.
24. + T lymphocytes and in neutrophils following intravenous immunoglobulin infusion. J. Clin. Immunol. 2010, 30:384-392.
25. Schleiffenbaum B., Spertini O., Tedder T.F. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J. Cell Biol. 1992, 119:229-238.
26. 2-integrin. J. Immunol. 1995, 155:1502-1514.
27. Ley K., Reutershan J. Leucocyte-endothelial interactions in health and disease. Handb. Exp. Pharmacol. 2006, 97-133.
28. von Gunten S., Schaub A., Vogel M., Stadler B.M., Miescher S., Simon H.U. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006, 108:4255-4259.
29. Ottonello L., Ghio M., Contini P., Bertolotto M., Bianchi G., Montecucco F., Colonna M., Mazzei C., Dallegri F., Indiveri F. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-β1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007, 47:1395-1404.
30. Ghio M., Ottonello L., Contini P., Amelotti M., Mazzei C., Indiveri F., Puppo F., Dallegri F. Transforming growth factor-β1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 2003, 102:1100-1107.
31. Vestweber D. Adhesion and signaling molecules controlling the transmigration of leukocytes through endothelium. Immunol. Rev. 2007, 218:178-196.
32. Rot A. Chemokine patterning by glycosaminoglycans and interceptors. Front. Biosci. 2010, 15:645-660.
33. Woodfin A., Voisin M.B., Nourshargh S. Recent developments and complexities in neutrophil transmigration. Curr. Opin. Hematol. 2010, 17:9-17.
34. Muller W.A. Mechanisms of transendothelial migration of leukocytes. Circ. Res. 2009, 105:223-230.
35. Carman C.V., Springer T.A. Trans-cellular migration: cell-cell contacts get intimate. Curr. Opin. Cell Biol. 2008, 20:533-540.
36. Burns A.R., Bowden R.A., MacDonell S.D., Walker D.C., Odebunmi T.O., Donnachie E.M., Simon S.I., Entman M.L., Smith C.W. Analysis of tight junctions during neutrophil transendothelial migration. J. Cell Sci. 2000, 113(Pt 1):45-57.
37. Gill V., Doig C., Knight D., Love E., Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation 2005, 112:2031-2039.
38. Durandy A., Kaveri S.V., Kuijpers T.W., Basta M., Miescher S., Ravetch J.V., Rieben R. Intravenous immunoglobulins-understanding properties and mechanisms. Clin. Exp. Immunol. 2009, 158(Suppl 1):2-13.
39. Levine D.S., Fischer S.H., Christie D.L., Haggitt R.C., Ochs H.D. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am. J. Gastroenterol. 1992, 87:91-100.